Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2013

01-12-2013 | Original Article

Epidemiology of Clostridium difficile-Associated Disease (CDAD): A Shift from Hospital-Acquired Infection to Long-Term Care Facility-Based Infection

Authors: Shashank Garg, Yusra R. Mirza, Mohit Girotra, Vivek Kumar, Samuel Yoselevitz, Ankur Segon, Sudhir K. Dutta

Published in: Digestive Diseases and Sciences | Issue 12/2013

Login to get access

Abstract

Background

Previous epidemiological studies on Clostridium-difficile-Associated Diarrhea (CDAD) have focused on hospitalized patients with nosocomial transmission. However, increasing numbers of patients with CDAD are being admitted to acute-care hospitals from long-term care facilities (LTCFs) and the local community. The purpose of our study was to study the changing epidemiological trends of CDAD patients admitted to an acute-care hospital and examine factors contributing to this shift in epidemiology.

Materials and Methods

This IRB-approved retrospective study included 400 randomly selected patients with a diagnosis of CDAD, admitted to an acute-care hospital between January, 2005 and December, 2010. CDAD was defined as ≥3 episodes of loose stools in <24 h with a positive Clostridium difficile stool toxin assay. The patients were divided into three groups: hospital-acquired CDAD, long-term care facility (LTCF)-acquired CDAD, and community-acquired CDAD. The groups were compared in terms of demographics, ICU admissions, hospital length of stay, co-morbidities, presenting complaint, and medication use. Patients who were hospitalized in the preceding 12 weeks or who had history of antibiotic use in the prior 8 weeks were excluded.

Results

Final analysis included 258 toxin-positive CDAD patients. Only 53 (20.6 %) patients had hospital-acquired CDAD. Patients from LTCFs (n = 119, 46.1 %) and the community (86 patients, 33.3 %) comprised 79.4 % of patients. The mean age for LTCF population was significantly higher than the hospital-acquired and community-acquired CDAD groups (p < 0.0001). The presenting complaint was categorized as diarrhea or non-diarrheal symptom. Other non-diarrheal symptoms included fever, abdominal pain and altered mental status. Only 15.2 % of LTCF patients had diarrhea as their presenting complaint (n = 18) as compared to 29.1 % of patients from the community (n = 25; p < 0.05). Most LTCF patients (n = 101, 84.8 %) had non-diarrheal symptoms as their presenting complaint as compared to only 61 patients from the community (70.9 %) (p < 0.05). Use of proton pump inhibitor (PPI) was more frequent in LTCF patients (73 %) and patients with hospital-acquired CDAD (69.8 %) as compared to patients with community-acquired CDAD (43 %) (p < 0.05). No valid indication was found for PPI use in 24.13 % of LTCF patients and 32.1 % of patients with community-acquired CDAD as compared to only 12.9 % of patients with hospital-acquired CDAD.

Conclusion

These observations suggest that CDAD originated predominantly in patients from LTCFs (46.1 %) and community (33.3 %) rather than from hospitalized patients (20.6 %). Diarrhea was the presenting complaint in LTCF patients in only 15.2 % of cases. Hence, CDAD should be suspected if LTCF patients present with symptoms such as abdominal pain, fever, or altered mental status along with loose stools. Majority of the LTCF patients were found to be on PPIs, a risk factor for CDAD, with as many as 24 % of these patients with no valid indication for their use.
Literature
1.
go back to reference Hall IC, O’Toole E. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child. 1935;49:390–402.CrossRef Hall IC, O’Toole E. Intestinal flora in newborn infants with a description of a new pathogenic anaerobe, Bacillus difficilis. Am J Dis Child. 1935;49:390–402.CrossRef
2.
go back to reference Bartlett JG, Moon N, Chang TW, et al. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology. 1978;75:778–782.PubMed Bartlett JG, Moon N, Chang TW, et al. Role of Clostridium difficile in antibiotic-associated pseudomembranous colitis. Gastroenterology. 1978;75:778–782.PubMed
3.
go back to reference George RH, Symonds JM, Dimock F, et al. Identification of Clostridium difficile as a cause of pseudomembranous colitis. BMJ. 1978;1:695.PubMedCrossRef George RH, Symonds JM, Dimock F, et al. Identification of Clostridium difficile as a cause of pseudomembranous colitis. BMJ. 1978;1:695.PubMedCrossRef
4.
go back to reference Kelly CP, LaMont JT. Clostridium difficile–more difficult than ever. N Engl J Med. 2008;359:1932–1940.PubMedCrossRef Kelly CP, LaMont JT. Clostridium difficile–more difficult than ever. N Engl J Med. 2008;359:1932–1940.PubMedCrossRef
5.
go back to reference Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466–472.PubMedCrossRef Pépin J, Valiquette L, Alary ME, et al. Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ. 2004;171:466–472.PubMedCrossRef
6.
go back to reference McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis. 2006;12:409–415.PubMed McDonald LC, Owings M, Jernigan DB. Clostridium difficile infection in patients discharged from US short-stay hospitals, 1996–2003. Emerg Infect Dis. 2006;12:409–415.PubMed
7.
go back to reference Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34(3):346–353.PubMedCrossRef Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002;34(3):346–353.PubMedCrossRef
8.
go back to reference McGlone SM, Bailey RR, Zimmer SM, et al. The economic burden of Clostridium difficile. Clin Microbiol Infect. 2012;18:282–289.PubMedCrossRef McGlone SM, Bailey RR, Zimmer SM, et al. The economic burden of Clostridium difficile. Clin Microbiol Infect. 2012;18:282–289.PubMedCrossRef
9.
go back to reference Vaishnavi C. Clinical spectrum & pathogenesis of Clostridium difficile associated diseases. Indian J Med Res. 2010;131:487–499.PubMed Vaishnavi C. Clinical spectrum & pathogenesis of Clostridium difficile associated diseases. Indian J Med Res. 2010;131:487–499.PubMed
10.
go back to reference McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204–210.PubMedCrossRef McFarland LV, Mulligan ME, Kwok RY, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med. 1989;320:204–210.PubMedCrossRef
11.
13.
go back to reference Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile–associated diarrhea: a review. Arch Intern Med. 2001;161:525–533.PubMedCrossRef Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile–associated diarrhea: a review. Arch Intern Med. 2001;161:525–533.PubMedCrossRef
14.
go back to reference Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330:257–262.PubMedCrossRef Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile colitis. N Engl J Med. 1994;330:257–262.PubMedCrossRef
15.
go back to reference Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis. 2004;38:640–645.PubMedCrossRef Gaynes R, Rimland D, Killum E, et al. Outbreak of Clostridium difficile infection in a long-term care facility: association with gatifloxacin use. Clin Infect Dis. 2004;38:640–645.PubMedCrossRef
16.
go back to reference Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294:2989–2995.PubMedCrossRef Dial S, Delaney JA, Barkun AN, et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005;294:2989–2995.PubMedCrossRef
17.
go back to reference Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–455.PubMedCrossRef Cohen SH, Gerding DN, Johnson S, et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010;31:431–455.PubMedCrossRef
18.
go back to reference Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999–2004. Emerg Infect Dis. 2007;13:1417–1419.PubMedCrossRef Redelings MD, Sorvillo F, Mascola L. Increase in Clostridium difficile-related mortality rates, United States, 1999–2004. Emerg Infect Dis. 2007;13:1417–1419.PubMedCrossRef
19.
go back to reference Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med. 1986;146:95–100.PubMedCrossRef Gerding DN, Olson MM, Peterson LR, et al. Clostridium difficile-associated diarrhea and colitis in adults. A prospective case-controlled epidemiologic study. Arch Intern Med. 1986;146:95–100.PubMedCrossRef
20.
go back to reference Burdon DW. Clostridium difficile: the epidemiology and prevention of hospital-acquired infection. Infection. 1982;10:203–204.PubMedCrossRef Burdon DW. Clostridium difficile: the epidemiology and prevention of hospital-acquired infection. Infection. 1982;10:203–204.PubMedCrossRef
21.
go back to reference Kim JH, Toy D, Muder RR. Clostridium difficile infection in a long-term care facility: hospital-associated illness compared with long-term care-associated illness. Infect Control Hosp Epidemiol. 2011;32:656–660.PubMedCrossRef Kim JH, Toy D, Muder RR. Clostridium difficile infection in a long-term care facility: hospital-associated illness compared with long-term care-associated illness. Infect Control Hosp Epidemiol. 2011;32:656–660.PubMedCrossRef
22.
go back to reference Guerrero DM, Nerandzic MM, Jury LA, et al. Clostridium difficile infection in a Department of Veterans Affairs long-term care facility. Infect Control Hosp Epidemiol. 2011;32:513–515.PubMedCrossRef Guerrero DM, Nerandzic MM, Jury LA, et al. Clostridium difficile infection in a Department of Veterans Affairs long-term care facility. Infect Control Hosp Epidemiol. 2011;32:513–515.PubMedCrossRef
23.
go back to reference McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999;20(1):43–50.PubMedCrossRef McFarland LV, Surawicz CM, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol. 1999;20(1):43–50.PubMedCrossRef
24.
go back to reference Quinn LK, Chen Y, Herwaldt LA. Infection control policies and practices for Iowa long-term care facility residents with Clostridium difficile infection. Infect Control Hosp Epidemiol. 2007;28:1228–1232.PubMedCrossRef Quinn LK, Chen Y, Herwaldt LA. Infection control policies and practices for Iowa long-term care facility residents with Clostridium difficile infection. Infect Control Hosp Epidemiol. 2007;28:1228–1232.PubMedCrossRef
25.
go back to reference Koretz RL. ACP Journal Club: review: proton-pump inhibitors are associated with increased risk for Clostridium difficile infection. Ann Intern Med. 2012. 157(4):JC2–13. Koretz RL. ACP Journal Club: review: proton-pump inhibitors are associated with increased risk for Clostridium difficile infection. Ann Intern Med. 2012. 157(4):JC2–13.
26.
go back to reference Metz DC. Long-term use of proton-pump inhibitor therapy. Gastroenterol Hepatol (NY). 2008;4:322–325. Metz DC. Long-term use of proton-pump inhibitor therapy. Gastroenterol Hepatol (NY). 2008;4:322–325.
27.
go back to reference Walker KJ, Gilliland SS, Vance-Bryan K, et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc. 1993;41:940–946.PubMed Walker KJ, Gilliland SS, Vance-Bryan K, et al. Clostridium difficile colonization in residents of long-term care facilities: prevalence and risk factors. J Am Geriatr Soc. 1993;41:940–946.PubMed
28.
go back to reference Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12:2–18.PubMedCrossRef Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect. 2006;12:2–18.PubMedCrossRef
Metadata
Title
Epidemiology of Clostridium difficile-Associated Disease (CDAD): A Shift from Hospital-Acquired Infection to Long-Term Care Facility-Based Infection
Authors
Shashank Garg
Yusra R. Mirza
Mohit Girotra
Vivek Kumar
Samuel Yoselevitz
Ankur Segon
Sudhir K. Dutta
Publication date
01-12-2013
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2013
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-013-2848-x

Other articles of this Issue 12/2013

Digestive Diseases and Sciences 12/2013 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.